Subscribe to our mailing list
Get regular updates delivered to your email box.
Thanks! Please check your email for a confirmation email.
The DNA repair inhibitor prexasertib shrank the tumors of a third of the ovarian cancer patients treated with it in a Phase 2 clinical trial, preliminary results show. Its developer, Eli Lilly, said the participants had recurring cancer that failed ... Read more